THREE DIMENSIONAL IMAGING OF THE EYE'S POSTERIOR POLE

长期的商业目标是带来广泛分布的、高利润的临床/医学研究软件产品线，用于人眼后极部的3D可视化。主要的科学目标是开发、调查和评估这样做的数学和计算算法方法。对于医学研究，这样的软件旨在了解一系列目前被误解和主要的致盲疾病的机制。在临床上，它的目的是早期诊断和治疗这些疾病，目前还不可能做到这一点。有针对性的主要疾病类别包括：视网膜下新生血管、黄斑变性、糖尿病视网膜病变和艾滋病相关视网膜病变。第二阶段的目标将集中于进一步研究算法方法，这些方法将解决第一阶段确定的局限性，并使后续产品成为一个广泛销售和盈利的产品。其具体目标是：(L)研究、开发和评估算法方法，以解决目前速度、稳健性、残余未对准、翘曲、自吸收和正文中描述的其他限制的限制；(2)使用包含已知几何荧光对象的模型眼对重建进行实验验证；以及(3)由视网膜专家对图像进行客观评估，他们将评估其临床实用性和图像质量改进方面的一致性。建议的商业应用：该产品将是扫描激光眼底镜S(SLO)的标准附件。在10年内，预计每年将售出至少100台ICG SLO，预计在适当的定价下，每一台SLO都将包含该软件产品。AutoQuant成像正在与一家主要的SLO制造商合作。

The long term end commercial objective is to lead to a widely distributed, highly profitable clinical/medical-research software product line for 3D visualization of the posterior pole of the human eye. The main scientific objective is to develop, investigate and evaluate mathematical and computational algorithm approaches for doing so. For medical research, such software is aimed at understanding the mechanisms of a wide range of presently misunderstood and predominant blinding diseases. Clinically, it is aimed at early diagnosis and treatment of these diseases, to an extent that is presently not possible. Specific targeted predominant disease classes include: subretinal neovascularization, macular degeneration, diabetic retinopathy, and AIDS related retinopathy. The Phase II objectives will focus upon further studying algorithm approaches that will address the limitations identified during Phase I and which will make the follow-on product one that is widely sold and profitable. The Specific Aims are to: (l) Study, develop and evaluate algorithm approaches that address the present limitations of speed, robustness, residual misalignment, warping, self absorption, and other limitations described in the text, (2) experimental validation of the reconstructions using a model eye that incorporates known geometric fluorescent objects, and (3), an objective evaluation of the images by expert retinal specialists, who will rate their clinical utility and consistency in image quality improvement. PROPOSED COMMERCIAL APPLICATIONS: The product will be a standard add-on to Scanning Laser Ophthalmoscope 's (SLO's). Within 10 years, it is expected that at least 100 ICG SLO's will be sold per year, and it is expect that with proper pricing each of these SLO's will incorporate this software product. AutoQuant Imaging is partnering with a major SLO manufacturer to do so.